Efficient three-drug cocktail for disease induced by mutant superoxide dismutase
Jasna Kriz1, Geneviève Gowing, Jean-Pierre Julien
1Centre for Research in Neurosciences, McGill University, Research Institute of the McGill University Health Centre, Montréal, Québec H3G 1A4, Canada.
Abstract:
There is currently no effective pharmacological treatment for amyotrophic lateral sclerosis (ALS). Because evidence suggests that multiple pathways may contribute to ALS pathogenesis, we tested in a mouse model of ALS (SOD1(G37R) mice) a combination approach consisting of three drugs for distinct targets in the complex pathway to neuronal death: minocycline, an antimicrobial agent that inhibits microglial activation, riluzole, a glutamate antagonist, and nimodipine, a voltage-gated calcium channel blocker. The efficacy of this three-drug cocktail was remarkable when administered in the diet from late presymptomatic stage (8-9 months). It delayed the onset of disease, slowed the loss of muscle strength, and increased the average longevity of SOD1(G37R) mice by 6 weeks. The protective effect of the treatment was corroborated by the reduced immunodetection signals for markers of gliosis and neurodegeneration in the spinal cord of SOD1(G37R) mice. These results indicate that such three-drug combination may represent an effective strategy for ALS treatment.
Insights
A novel three-drug combination therapy shows promise for treating amyotrophic lateral sclerosis (ALS). This treatment delays disease onset, improves muscle strength, and extends lifespan in a mouse model, offering hope for effective ALS pharmacotherapy.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Amyotrophic lateral sclerosis (ALS) currently lacks effective pharmacological treatments.
- Multiple pathways are implicated in ALS pathogenesis, suggesting combination therapy may be beneficial.
Purpose of the Study:
- To evaluate the efficacy of a three-drug combination therapy in a mouse model of ALS.
- To assess the impact of minocycline, riluzole, and nimodipine on disease progression and survival.
Main Methods:
- Administered a combination of minocycline, riluzole, and nimodipine via diet to SOD1(G37R) mice from a late presymptomatic stage (8-9 months).
- Monitored disease onset, muscle strength, and longevity.
- Analyzed spinal cord tissue for markers of gliosis and neurodegeneration.
Main Results:
- The three-drug cocktail significantly delayed ALS onset and slowed muscle strength loss in SOD1(G37R) mice.
- Average longevity of treated mice increased by 6 weeks.
- Reduced markers of gliosis and neurodegeneration were observed in the spinal cords of treated mice.
Conclusions:
- A combination therapy of minocycline, riluzole, and nimodipine demonstrates significant neuroprotective effects in an ALS mouse model.
- This multi-target approach offers a potential effective strategy for future ALS treatment development.
